Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

Inclusion Criteria:

Histological/cytological documented non-small cell lung cancer (NSCLC). Documentation of recurrence required if treated with surgical resection and/or external beam radiation therapy (XRT) with curative intent and now have recurrent disease.
Fresh tissue biopsy material for genomics analysis prior to initiating dasatinib. If prior XRT, tissue biopsy must be outside XRT field. Biopsy must be after any prior chemotherapy.

Prior treatment (tx) to include one of the following:

At least 1 prior systemic regimen (IV or oral agent) for Stage IV NSCLC or for recurrent disease.
Recurrence within 12 months after completion of systemic neoadjuvant/adjuvant chemotherapy for early stage NSCLC.
Combined modality platinum-based tx for Stage III NSCLC.
Prior XRT permitted if ≥1 week since completion, XRT must be <25% of bone marrow reserve.
At least one, non-radiated, measurable lesion (per RECIST).
Age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) 0-2.

Adequate Organ Function:

Total bilirubin < Upper limit normal (ULN)
Hepatic enzymes (AST, ALT) ≤2.5x ULN
Serum creatinine <1.5x ULN
Hemoglobin ≥9 gm/dL
Neutrophil count (ANC/AGC) ≥1500 per μL
Platelets ≥100,000 per μL
Prothrombin time (PT)/a Partial thromboplastin time (PTT) ≤1.5x control
No other serious medical or psychiatric illness.
Ability to take oral medication (dasatinib must be swallowed whole).
Women of childbearing potential must have negative serum pregnancy test ≤72 hours and not >7 days prior to starting study drug.
Sexually active males and females of reproductive potential must agree to use adequate method of contraception during tx and for at least 4 weeks after study drug stopped.
Signed, written informed consent including Health Insurance Portability and Accountability Act (HIPAA) according to institutional guidelines.

Exclusion Criteria:

Previous or concomitant malignancy in past 2 years other than curatively treated carcinoma in situ of cervix, or basal cell/squamous cell carcinoma of the skin.
Prior tx with dasatinib or other agents that inhibit Src.
Evidence of symptomatic pleural effusions (grade 2) unless undergo therapeutic thoracentesis as part of non-study care. Successful pleurodesis allowed. Patients who require supplemental oxygen or with oxygen saturation on room air <89% are not eligible. Pericardial effusions of any grade are not eligible.
Untreated documented symptomatic central nervous system (CNS) metastases.

Cardiac Symptoms:

Uncontrolled angina, congestive heart failure(CHF)or myocardial infarction within 6 months
Diagnosed congenital long QT syndrome
Any h/o clinically significant ventricular arrhythmias
Prolonged QT corrected (QTc) interval on pre-entry EKG (>450 msec)
Uncontrolled B/P as defined as >160/90 on B/P therapy
Hypokalemia or hypomagnesaemia if it cannot be corrected.
H/o diagnosed congenital acquired bleeding disorders.
Ongoing or recent (≤3 months) significant (≥grade 3) GI bleeding.

Con Meds:

Drugs having risk of causing Torsades de Pointes (must stop drug 7 days before dasatinib);
Current therapeutic dose unfractionated heparin, low-molecular weight heparin, or coumadin therapy;
St. John's Wort must be stopped while on dasatinib;
IV bisphosphonates stopped 2 weeks pre/6 weeks post dasatinib.
Prisoners/subjects compulsorily detained for tx of psychiatric and/or physical illness.
Pregnant or breastfeeding.
Active or uncontrolled infection requiring IV antibiotics.
Impairment of GI function/disease that may alter absorption of dasatinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
Received investigational drugs ≤4 weeks prior to starting study drug and/or not recovered from side effects of such therapy. Any other anti-neoplastic and/or molecular therapy must be discontinued 7 days prior to starting dasatinib.